Outcome of daily cisplatin with thoracic chemoradiotherapy in advanced non-small cell lung cancer patients with comorbid disorders: a pilot study.
Yazarlar (7)
Hüriye Şenay Kızıltan
Bezm-İ Âlem Vakıf Üniversitesi, Türkiye
Bezm-İ Âlem Vakıf Üniversitesi, Türkiye
Doç. Dr. Ayşe GÜNEŞ BAYIR Bezm-İ Âlem Vakıf Üniversitesi, Türkiye
Didem Taştekin
Doç. Dr. Ganime Çoban Bezm-İ Âlem Vakıf Üniversitesi, Türkiye
Ali Hikmet Eriş
Prof. Dr. Teoman Aydın Bezm-İ Âlem Vakıf Üniversitesi, Türkiye
Prof. Dr. Alpaslan Mayadağlı Bezm-İ Âlem Vakıf Üniversitesi, Türkiye
| Makale Türü |
Özgün Makale
(SSCI, AHCI, SCI, SCI-Exp dergilerinde yayınlanan tam makale)
|
||
| Dergi Adı | ASIAN PACIFIC JOURNAL OF CANCER PREVENTION (Q4) | ||
| Dergi ISSN | 1513-7368 Wos Dergi Scopus Dergi | ||
| Dergi Tarandığı Indeksler | SCI-Expanded | ||
| Makale Dili | İngilizce | Basım Tarihi | 01-2014 |
| Cilt / Sayı / Sayfa | 15 / 20 / 8591–8594 | DOI | 10.7314/APJCP.2014.15.20.8591 |
| Makale Linki | http://journal.waocp.org/?sid=Entrez:PubMedid=pmid:25374173key=2014.15.20.8591 | ||
| UAK Araştırma Alanları |
Veteriner Gıda Hijyeni ve Teknolojisi
|
||
| Özet |
BackgroundLung cancer is the most common cancer in males worldwide. The principal mode of treatment in the early stage of non-small cell lung cancer (NSCLC) is surgery. However, five-year survival is only about 15% for all stages. The aim is to investigate the effect of daily low dose cisplatin concurrently with radiation therapy in advanced NSCLC patients with poor performance status.Materials and methodsTen patients diagnosed as inoperable Stage IIIB NSCLC with comorbid disease were assessed retrospectively in Bezmialem Vakif University, Faculty of Medicine, Department of Radiation Oncology, between 2011 to 2013. ECOG performance status was between 3 and 4. Cisplatin was administered at 6 mg/m2 daily, for 5 days a week concurrently with radiotherapy using 160-200 cGy daily fractions, 54 Gy being the lowest and 63 Gy being the highest dose.ResultsComplete response at the primary tumour site was obtained in 20% patients. Grade I esophagitis was seen 70 percent of patients, and the grade II haematological toxicity rate was 20%. Median survival time was 7 months.ConclusionsMedian survival time was reasonable, despite the patients ECOG performance status of 3-4, which is similar to groups even without comorbid disorders in comparison to other published papers in the literature. Acceptable toxicity, high response rates and quality of life of patients are the other favourable features. |
| Anahtar Kelimeler |
| Daily cisplatin | comorbid disease | thoracic radiochemotherapy | ECOG performance status | NSCLC |
BM Sürdürülebilir Kalkınma Amaçları
| Atıf Sayıları | |
| Web of Science | 3 |
| Google Scholar | 5 |